OQROGet OQRO Pro
Insider trade

Steris (STE)CEO sold ~$656K

Daniel A Carestio, CEO at Steris, sold ~$656K of Steris shares.

~$656K
Approx. value · 3,054 sh @ $214.64
65K
Holds after · shares reported
Traded
Jun 4, 2026
Filed
Jun 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 16, 2026CongressDisclosed purchase of STE — reported range $1,001 - $15,000
  2. Mar 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 31, 2026, STERIS plc (the “Company”) and Michael J. Tokich, the Company’s former Chief Financial Officer, entered into an amendment (the “Amendment”) to the Transition Agreement, dated August 5, 2025, between the Company and Mr. Tokich (the “Agreement”).”
  3. Apr 8, 2026FDAFDA device clearance: SYSTEM 1E Liquid Chemical Sterilant Processing System, Model P6700; SYSTEM 1 endo Liquid Chemical Sterilant Processing System, Model P6900
  4. Apr 8, 2026FDAFDA device clearance: Celerity 5 HP Biological Indicator (LCB052)
  5. Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
  6. Apr 29, 2026CongressDisclosed purchase of STE — reported range $1,001 - $15,000
  7. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  8. Apr 30, 2026CongressDisclosed purchase of STE — reported range $1,001 - $15,000
  9. May 1, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders.”
  10. May 1, 2026CongressDisclosed purchase of STE — reported range $1,001 - $15,000
  11. May 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 31, 2026, Pierre Boulud was appointed to serve on the Audit Committee of the Board and the Compliance and Technology Committee of the Board.”
  12. May 11, 2026Company filing · Form 8-K · ResultsReported its results
  13. May 11, 2026Congress · 1 personMembers of Congress: 2 purchases
  14. May 12, 20265% stakeSTATE STREET CORPORATION reported a passive stake (13G) of 5.1%
  15. May 13, 2026CongressDisclosed purchase of STE — reported range $1,001 - $15,000
  16. May 15, 2026FDARecall: HarmonyAIR A-Series Surgical Lighting System
  17. May 15, 2026FDARecall: HarmonyAIR A-Series Surgical Lighting System
  18. May 15, 2026FDARecall: ALYON Surgical Lighting System
  19. Jun 2, 2026InsiderDirector sold ~$310K of STE shares in the open market
  20. Jun 4, 2026 · this disclosureInsiderCEO sold ~$656K of STE shares in the open market

What came next

  1. Jun 5, 2026InsiderCEO sold ~$291K of STE shares in the open market
  2. Jun 15, 2026InsiderOfficer sold ~$297K of STE shares in the open market
  3. Jun 24, 2026FDAFDA device clearance: AMSCO 700 Steam Sterilizer
  4. Jul 13, 2026CongressDisclosed sale of STE — reported range $1,001 - $15,000
  5. Jul 24, 2026CongressDisclosed partial sale of STE — reported range $1,001 - $15,000
  6. Jul 27, 2026CongressDisclosed partial sale of STE — reported range $1,001 - $15,000
  7. Jul 29, 2026CongressDisclosed partial sale of STE — reported range $1,001 - $15,000
  8. Jul 31, 2026CongressDisclosed partial sale of STE — reported range $1,001 - $15,000
  9. Aug 5, 2026Company filing · Form 8-K · Results, RestructuringAnnounced job cuts, closures or a restructuring, and reported its results“On August 5, 2026, the Company announced a targeted consolidation plan (the “Consolidation Plan”) to consolidate existing manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina.”
  10. Aug 12, 2026InsiderDirector sold ~$957K of STE shares in the open market
  11. Aug 25, 2026CongressDisclosed sale of STE — reported range $100,001 - $250,000
  12. Sep 15, 2026CongressDisclosed sale of STE — reported range $15,001 - $50,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Steris

For Steris, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports and 18 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its STE page.

Other recent filings by Daniel A Carestio, President and CEO

The full history of Daniel A Carestio, President and CEO is on the profile page.

How this filing works

Other disclosures at Steris

Everything OQRO holds on this company is on its STE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data